Metastatic Breast Cancer
Conditions
Brief summary
We are trying to develop better ways to detect when cancer therapies are working.
Interventions
None listed
Sponsors
University of Michigan Rogel Cancer Center
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1.Females at least 18 years of age 2 Diagnosis of metastatic breast cancer 3.ECOG Score of 0-2 4.Treating oncologist has decided to initiate any new systemic therapy with emphasis on recruiting patients commencing a taxane-based regimen. Taxine-based therapy may be docetaxel or paclitaxel, and it can be given on any schedule,including weekly or every 3 weeks. Other treatment can include non-taxane chemotherapy or trastuzumab-with or without other therapy. 5.Patient is willing to return for one or more additional \ 18 mL blood draw (s) at 24-48-, and /or 72 hours and \ 3-4 weeks after the initiation of therapy.At a minimum, patients must donate blood at baseline, one intermediate interval (24, 48, 72 hr) and at \ 3-4 weeks 6.Signed Informed Consent Form \-
Exclusion criteria
Patient is unable and unwilling to provide a blood specimen at a minimum of one of the intermediate blood draw time points at 24, 48, or 72 hours -
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine the feasibility of detecting Bcl2 expression and apoptosis in CTCs | Prospective |
Countries
United States
Outcome results
None listed